Alvarez W.C. The motor functions of the intestine from a new point of view. JAMA, 1915, 65: 388-394.

Drossman D.A. The Functional Gastrointestinal Disorders and the Rome III Process. Gastroenterology, 2006, 130(5): 1377-1390.

Celebi S, Acik Y, Deveci SE et al. Epidemiological features of irritable bowel syndrome in a Turkish urban society. J. Gastroenterol. and Hepatol., 2004, 19(7): 738-743.

Hungin AP, Chang L, Locke GR et al. 2005 Irritable bowel syndrome in the United States: Prevalence, symptom patterns and impact. Aliment. Pharmacol. Ther., 2005, 21: 1365-1375.

Agreus L, Talley NJ, Svardsudd K et al. 2000 Identifying dyspepsia and irritable bowel syndrome: The value of pain or discomfort, and bowel habit descriptors. Scand. J. Gastroenterol., 2000, 35: 142-151.

Яковенко А.В., Иванов А.Н., Прянишникова А.С. и др. Патогенетические подходы в лечении синдрома раздраженного кишечника. Лечащий врач, 2001, 7. / Yakovenko A.V., Ivanov A.N., Pryanishnikova A.S. et al. Pathogenetic approaches to therapy of irritable intestine syndrome. Lechaschiy Vrach, 2001, 7.

Kanazawa M, Palsson OS, Thiwan SI et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am. J. Gasroenterol., 2008, 103: 2550-2561.

Simren M, Barbara G, Flint HJ et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut., 2013, 62: 159-176.

Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophisiology. The confluence of increased permeability, inflamation, and, pain in irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver. Physiol., 2012, 303: 775-785.

Shulman RJ, Jarrett ME, Cain KC et al. Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J. Gastroenterol. 2014. doi: 10.1007/s00535-013-0919-6..
DOI: 10.1007/s00535-013-0919-6

Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J. Gastroenterol., 2011, 46: 421-431.

Koloski NA, Jones M, Kalantar J et al. The braingut pathways in functional gastrointestinal disorders is bidirectional: a 12-year prospective population- based study. Gut., 2012, 61: 1284-1290.

Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Ann. Rev. Med., 2011, 62: 381-396.

Stasi C, Rosselli M, Bellini M et al. Altered neuro- endocrine-immune pathways in irritable bowel syndrome: the top-down and the bottomup model. J. Gastroenterol., 2012, 47: 1177-1185.

Турко Т.В., Махов В.М. Синдром раздраженного кишечника. РМЖ, 2006, 1. / Turko T.V., Makhov V.M. Irritable intestine syndrome. RMZ, 2006, 1.

Махов В.М., Ромасенко Л.В., Турко Т.В., Шептак Н.Н. Синдром раздраженного кишечника – коморбидное соматопсихическое заболевание. РМЖ, Прил. к матер. конгр. Человек и лекарство, 2012, 2. / Makhov V.M., Romasenko L.V., Turko T.V., Sheptak N.N. Irritable intestine syndrome – comorbide somatopsychic disease. RMZ, app. to

materials of congress Chelovek I Lekarstvo, 2012, 2.

Мадиш А., Хольтман Ж., Пляйн К., Хотц Дж. Лечение синдрома раздраженного кишечника препаратами растительного происхождения: результаты двойного слепого рандомизированного плацебо-контролируемого многоцентрового исследования. Российский медицинский журнал гастроэнтерологии, 2004, 19: 271-279. / Madish A., Kholtman Z., Plyain K, Khotz J. Therapy of irritable intestine syndrome by vegetable origin drugs: results of double blind randomized placebo-controlled multi-center study. Rossiysky Meditsinsky Zhurnal Gastroenterologii, 2004, 19: 271-279.18. Simmen U, Kelber O, Jaggi R et al. Relevance of the herbal combination of STW 5 for its binding affinity to the muscarinic M3 receptor. Naunyn-Schmiede-berg’s Arch. Pharmacol., 2003, 367(Suppl. 1A): R22.